AstraZeneca: AZD7442 filed for emergency approval
(CercleFinance.com) - AstraZeneca announced on Tuesday that it has filed an emergency application in the United States for its prophylactic treatment against Covid-19.
The biopharmaceutical company said it had submitted its application for AZD7442, a long-acting monoclonal antibody (LABA) combination, to the US Food and Drug Administration (FDA).
If approved, AZD7442 would become the first LAAB molecule approved for disease prevention.
In a statement, AstraZeneca said that it is relying on Phase III data that showed a "statistically significant" reduction in the development of symptomatic forms of the disease.
Originally discovered by Vanderbilt University Medical Center before being licensed to AstraZeneca last year, AZD7442 is derived from the plasma of convalescent patients who have recovered from the Covid infection.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The biopharmaceutical company said it had submitted its application for AZD7442, a long-acting monoclonal antibody (LABA) combination, to the US Food and Drug Administration (FDA).
If approved, AZD7442 would become the first LAAB molecule approved for disease prevention.
In a statement, AstraZeneca said that it is relying on Phase III data that showed a "statistically significant" reduction in the development of symptomatic forms of the disease.
Originally discovered by Vanderbilt University Medical Center before being licensed to AstraZeneca last year, AZD7442 is derived from the plasma of convalescent patients who have recovered from the Covid infection.
Copyright (c) 2021 CercleFinance.com. All rights reserved.